Opinion|Videos|July 29, 2024
How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor
Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.
Advertisement
Video content above is prompted by the following question(s):
- How do you balance the potential clinical benefits of CDK4/6 inhibitors with the cost considerations when making treatment decisions for early breast cancer patients?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
FDA OKs Zidesamtinib as New Option for Resistant ROS1+ NSCLC
2
Cognitive Rehabilitation Improves Functional Outcomes in Long COVID Brain Fog
3
PMOS Linked to 4-Fold Atherosclerotic Heart Disease Risk in 2.5 Million US Women
4
CAR T-Cell Therapy Shows Promise in Refractory Myasthenia Gravis, Evidence Still Limited
5